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Abstract 40 
 41 
Aims: To explore whether long-term intervention with dietary nitrate ((NO3-), a potential 42 
tolerance-free source of beneficial vasoactive nitric oxide) and spironolactone (to oppose 43 
aldosterone’s potential deleterious cardiovascular effects) improve cardiac structure/function, 44 
independent of blood pressure (BP), in patients with/at risk of type 2 diabetes (a population at 45 
risk of heart failure).  46 
Methods: A sub-sample of participants in our double-blind, randomised, factorial-design 47 
intervention (VaSera) trial of active beetroot juice as a nitrate source (≤11.2 mmol) or 48 
placebo (nitrate-depleted) beetroot juice, and either ≤50 mg spironolactone or ≤16 mg 49 
doxazosin (control), had trans-thoracic cardiac ultrasounds at baseline (n=105), 3 and 6 50 
months (n=87) of intervention. Analysis was by modified intention-to-treat.  51 
Results: Nitrate-containing juice (n=40) decreased left ventricular (LV) end diastolic volume: 52 
-6.3 mL (95% confidence intervals (CI) -11.1,-1.6), and end systolic volume: -3.2 mL (-5.9,-53 
0.5), and increased end diastolic mass/volume ratio: +0.04 (0.00,0.07), relative to placebo 54 
juice (n=47). Spironolactone (n=44) reduced relative wall thickness compared to doxazosin 55 
(n=43): -0.01 (-0.02,-0.00). Whilst spironolactone reduced LV mass index relative to 56 
baseline: -1.48 g/m2.7 (-2.08,-0.88), there was no difference versus doxazosin: -0.85 g/m2.7 (-57 
1.76,0.05). Spironolactone also decreased the E/A ratio: -0.12 (-0.19,-0.04) and increased S’ 58 
(a tissue-Doppler systolic function index) by 0.52 (0.05,1.0 cm/s). BP did not differ between 59 
the juices, or between the drugs. 60 
Conclusions: 6 months' dietary nitrate decreased LV volumes ~5%, representing new, 61 
sustained, BP-independent benefits on cardiac structure, extending mechanisms characterised 62 
in pre-clinical models of heart failure. Spironolactone’s effects on cardiac remodeling and 63 
systo-diastolic function whilst confirmatory, were independent of BP. 64 
 65 
Key words: dietary nitrate, beetroot juice, echocardiography, cardiac remodelling, nitrate-66 
nitrite-NO pathway, type 2 diabetes,  67 
 68 
What is already known about this subject: 69 
• Type 2 Diabetes (T2DM) is a major risk factor for heart failure (HF), especially with 70 
preserved ejection fraction (HFpEF), for which there are no established cures 71 
• Acutely, inorganic nitrite improves central haemodynamics and left heart filling 72 
pressures in patients with HFpEF 73 
• Chronic administration of nitrite (4 and 9 weeks’) in murine models of heart failure 74 
reduces left ventricular (LV) volumes 75 
What this study adds: 76 
• In the longest study yet completed with dietary nitrate, 6 months’ beetroot juice 77 
decreased LV volumes ~5% 78 
• This was independent of blood pressure and represents a sustained beneficial effect on 79 
cardiac structure 80 
• Dietary nitrate has potential to prevent diabetic cardiomyopathy/heart failure 81 
82 
Introduction 83 
 84 
Type 2 Diabetes (T2DM) is a major risk factor for heart failure (HF) [1], with either reduced 85 
(HFrEF) or preserved ejection fraction (HFpEF) [2].  Patients with T2DM are particularly 86 
susceptible to increased LV volumes with drugs which cause fluid retention/increase pre-87 
load, such as pioglitazone [3]. Conversely, simply lowering BP with losartan or atenolol in 88 
the LIFE study did not alter LV volumes in patients with diabetes [4].  89 
 90 
Decreased production of nitric oxide (NO), a key regulator of vascular homeostasis, by NO 91 
synthases and/or decreased bioavailability of NO, (eg: due to excess reactive oxygen species, 92 
ROS), is implicated in vascular dysfunction in cardiovascular disease and T2DM [5], LV 93 
diastolic dysfunction [6], HF [7], and HFpEF [8]. However, standard approaches to 94 
supplement NO using organic nitrates, such as isosorbide mononitrate, lack benefit [9]. This 95 
loss of effect with chronic ingestion may be due to nitrate tolerance via decreased 96 
bioactivation, increased ROS production and endothelial dysfunction [10]. An alternative 97 
therapeutic approach may be via dietary inorganic nitrate (NO3-), as found in green leafy 98 
vegetables and beetroot [11]. Nitrate is reduced to nitrite (NO2-) via the entero-salivary 99 
circulation, and further reduced to NO in a hypoxia-dependent process. This “nitrate-nitrite-100 
NO pathway” appears to lack these tolerance issues [12], suppress ROS [13] and reverse 101 
endothelial dysfunction [14], and has been extensively investigated clinically in studies up to 102 
4-6 weeks, particularly for blood pressure (BP)-lowering [12][14-16][17]. By contrast, 103 
patients with T2DM appear to lack any effect of dietary nitrate on BP [17][18][19].   104 
 105 
However, we recently reported that dietary nitrate lowered central aortic systolic BP (–2.6 106 
mm Hg [–4.5 to –0.75 mm Hg], (mean [95% CIs]) p=0.007), despite no effect on brachial 107 
BP, with the main haemodynamic findings of the current study [20]. This is consistent with 108 
our findings whereby inorganic nitrite acutely and selectively lowers central aortic pressure 109 
through a normoxia-dependent dilatory effect on conduit arteries (radial) in healthy 110 
volunteers [21, 22], and selectively dilates epicardial coronary arteries in patients undergoing 111 
coronary angiography [23].  112 
 113 
Another important cause of heart failure in patients with T2DM is myocardial infarction due 114 
to coronary artery disease, with nitrite displaying a potential role  in coronary ischaemia-115 
reperfusion injury (IRI) [24], acute ST-elevation myocardial infarction (STEMI) [25, 26], and 116 
remote ischaemic preconditioning (RIPC) [27, 28]. Moreover, Lefer and colleagues showed 117 
that chronic, 4-9 weeks’ oral sodium nitrite supplementation prevented the increases in end-118 
diastolic volume (EDV) and end-systolic volume (ESV)) in murine models of IRI following 119 
left coronary artery occlusion  [29], and pressure-overload induced LVH with trans-aortic 120 
constriction  [7].  121 
 122 
In contrast to NO-supplementation, mineralocorticoid antagonists are established treatments 123 
in HF and hypertension, combatting aldosterone-mediated deleterious cardiovascular effects 124 
[30], with 40 weeks’ spironolactone improving LV mass, arterial stiffness measured as pulse 125 
wave velocity (PWV), augmentation index, and aortic distensibility, in parallel with the 126 
reduction in BP, over in patients with stage 2-3 chronic kidney disease [31].  127 
 128 
Given the potential for long-term dietary nitrate, and spironolactone, to improve cardiac 129 
structure or function, alongside, or independently of, any changes in arterial haemodynamics, 130 
we prospectively performed echocardiograms in a sub-sample of patients participating in our 131 
VaSera factorial RCT [20, 32], with the a priori intention of exploring these specific 132 
mechanisms independently of BP, following a chronic, 6 months’ treatment  with dietary 133 
nitrate (‘Beet-it®’ or ‘Beet-it Sport®’ beetroot juice), and/or spironolactone.  134 
 135 
The primary hypothesis for the main study was that spironolactone, dietary nitrate, or both 136 
could reduce arterial stiffness, measured by PWV, as a treatment target formally independent 137 
of BP. We have recently reported that the primary outcome, change in arterial stiffness as 138 
cardio-ankle vascular index (CAVI), a nominally BP-independent measure, was not different 139 
between spironolactone and doxazosin, P=0.08 [20]. Also, and against the hypothesis, the 140 
secondary outcome, aortic PWV by arteriography adjusted for peripheral BP differences at 141 
baseline and BP change between trial arms from the trial’s start to end, was lower with 142 
doxazosin than spironolactone (P=0.045). Dietary nitrate had no effect on PWV.  143 
 144 
 145 
 146 
147 
Methods 148 
 149 
Study Population 150 
A sub-sample of patients (with, or at risk of, T2DM) who were consented and randomised in 151 
our VaSera factorial RCT had serial trans thoracic cardiac ultrasound performed during the 152 
course of the study. The study design and methods have previously been described in detail 153 
[32]. Briefly, participants with or at risk of T2DM were recruited from Guy’s and St Thomas’ 154 
Hospitals, London, UK and surrounding areas between 2013-2015. Inclusion criteria were 155 
age 18-80 years, clinically diagnosed T2DM or at risk of T2DM (as body mass index (BMI) 156 
≥27 kg/m2, positive family history or glucose intolerance after 75g challenge), ability to 157 
understand and comply with the protocol. Exclusion criteria: interfering chronic illness, 158 
adverse reaction to either drug, known allergy to beetroot, eGFR <45 mL min-1, HbA1c 159 
>11% (97mM/M), pregnant, breast feeding or atrial fibrillation.  160 
The results for the primary outcome – (arterial stiffness) are described above and have  been 161 
published separately [20].  The study was reviewed and approved by Central London 162 
National Research Ethics Service (NRES) and took place in the Clinical Research Facility 163 
(CRF) of St Thomas’s Hospital. (Clinical trial registration: ISRCTN25003627/ DOI 164 
10.1186/ISRCTN25003627). After initial consent and screening/familiarisation, visit 1 (V1), 165 
and having met inclusion criteria, patients were invited to return for double randomisation (in 166 
blocks of 6) at visit 2 (V2), with simultaneous allocation to both types of intervention for 167 
each patient, therefore into 1 of 4 groups [32]; see Figure 1 for Study Flow Diagram. After 168 
cardiac and vascular measurements, treatments were: either spironolactone 12.5mg once daily 169 
for one week titrated to twice daily, OR doxazosin 2mg once daily for one week titrated to 170 
twice daily, AND either nitrate -containing beetroot juice (BEET-IT®, nitrate 4.5mmol/day) 171 
or placebo beetroot juice. The juices were identical in appearance, smell and taste, with the 172 
nitrate having been removed from placebo juice by ion exchange (nitrate ~0mmol/day). 173 
Following two check-up visits (V3 and V4; 2 and 8 weeks, respectively), cardiac and 174 
vascular measures were repeated at 3 months (V5). Then, provided there were no 175 
contraindications, medication doses were increased (to spironolactone 25mg twice daily or 176 
doxazosin 8mg twice daily) and to more concentrated nitrate -containing beetroot juice 177 
(BEET-IT® Elite Sports Shot, ~11.2mmol nitrate/day, or matching placebo juice, ~0 mmol 178 
nitrate/day). The final visit (V6) was at 6 months’ post-randomisation, when V2 and V5 179 
cardiovascular assessments were repeated.  180 
Thus, in this factorial design, approximately half the patients were randomised to active, 181 
nitrate-containing beetroot juice, and the other half to the placebo nitrate-depleted juice (with 182 
no difference in BP expected, based on other studies of dietary nitrate in patients with T2DM 183 
described above). Also, half the patients were randomised to spironolactone, and the other 184 
half to doxazosin as control (expected to produce similar changes in BP from baseline, but no 185 
difference between the treatments). The factorial design is intended to permit determination 186 
of the independent effects of nitrate v placebo, and spironolactone v doxazosin, following 187 
testing for drug-dietary nitrate interactions for BP and for echocardiographic parameters.  188 
 189 
Echocardiography: Echocardiography was added to the protocol and offered to as many of 190 
the patients as possible, to explore mechanisms related to standard cardiac structure and 191 
function assessments, in parallel with the key haemodynamic outcome measures of the main 192 
study.  193 
 194 
Trans-thoracic cardiac ultrasound was performed using a GE Vivid 7 Ultrasound system. All 195 
measurements were performed by two expert operators and all images analysed by a single 196 
operator blinded to the intervention. Acquisitions were individually optimized for depth, gain, 197 
and frame rate to maximize image quality and minimize inconsistency in acoustic windows 198 
prior to analysis. Standard M-mode and 2D imaging was undertaken at rest. Images were 199 
saved in raw data format for offline analysis. Left atrial volume (LAV) was calculated by the 200 
ellipsoid method and subsequently normalized to body surface area to obtain left atrium 201 
volume index (LAVI). Recommendations of the American Society of Echocardiography and 202 
the European Association of Cardiovascular Imaging [33] were used to estimate left 203 
ventricular mass (LVM) which was indexed to height2.7, for LVM index (LVMI) to avoid 204 
systematic misclassification of cardiovascular risk in overweight and obesity - likely in these 205 
patients. Left ventricular ESV and EDV were measured using Simpson’s method and to 206 
estimate ejection fraction (EF). The ratio between LVM and EDV (mass/volume, M/V ratio) 207 
was calculated. Left ventricular (LV) systolic function was evaluated by peak systolic tissue 208 
Doppler imaging (TDI) of S’ wave (averaged between septal and later mitral annulus) and 209 
global longitudinal strain (GLS) assessed by 2-dimensional speckle tracking 210 
echocardiography. Diastolic function of the left ventricle was estimated by conventional 211 
Doppler mitral inflow (ratio of transmitral Doppler early (E) to late (A) filling velocity (E/A)) 212 
and tissue Doppler imaging (TDI) of mitral annulus (ratio of transmitral Doppler early filling 213 
velocity (E) to tissue Doppler early diastolic mitral annular velocity (E′) – (E/E’)), as per 214 
recommendations [34] as was the ratio E/E’ for evaluating LV filling pressure.  215 
 216 
Statistical considerations  217 
Analyses were conducted by our independent biostatistician (SM) modified intent-to-treat, 218 
consisting of all randomised patients except those with no outcome data at any follow up 219 
visit. Patients with missing data at some visits were included, and we assumed that data were 220 
missing at random (i.e. unrelated to the unobserved value). We used mixed effect models to 221 
estimate the effect of the interventions, and included gender, age, ethnicity (European, 222 
African-Caribbean, West African and other), a diagnosis of diabetes and the baseline value of 223 
the outcome as covariates. This was a pre-specified/prospectively-conducted, hypothesis-224 
generating, exploratory mechanistic part of the main study.  Thus, we present least squares 225 
mean changes from baseline and differences between drugs and between juices averaged over 226 
both follow-up visits for each outcome, with 95% confidence intervals (95% CI), rather than 227 
as hypothesis-testing P-values, in accordance with the recent editorial, “Statistical reporting 228 
of clinical pharmacology research” [35].   229 
 230 
231 
Results  232 
One hundred and five participants had echocardiograms at baseline (V2), of whom 87 (83%) 233 
also had follow-up data at V5 (3 months) and V6 (6 months); see Figure 2, CONSORT 234 
diagram. Participant details and baseline echo parameters in each treatment arm are shown in 235 
Table 1. Baseline LVMI (mean±SD) was 53±13.5g/m2.7; 52% met criteria for LV 236 
hypertrophy (LVH) [33], whilst 95% had normal LV filling pressure (average E/A 1±0.4, 237 
E/E’ 7.8±2.2).  238 
Haemodynamic Parameters  239 
Spironolactone and doxazosin both reduced systolic BP (SBP) by about 6 mmHg compared 240 
to baseline by with no difference between treatments (Table 2, Figure 3 (A-B)). Changes in 241 
diastolic BP (DBP) were also similar on each drug (~5 mmHg); see Figure 3 (C-D) with no 242 
change in heart rate (HR). There were no differences in brachial SBP, DBP or HR between 243 
nitrate-containing versus nitrate-depleted juice (Figure 4). No drug-dietary nitrate 244 
interactions were detected for BP or for echocardiographic parameters; therefore, the effects 245 
of the drugs and dietary nitrate were estimated from models with no interaction term. 246 
Echocardiographic Morphological Parameters 247 
Compared to placebo juice (n=47), nitrate-containing beetroot juice (n=40) decreased EDV: -248 
6.33 mL (-11.1,-1.57) and ESV: -3.2 mL (-5.9,-0.5); see Table 2 and Figure 5. Also, EDV 249 
and ESV decreased relative to baseline on nitrate-containing beetroot juice: -4.77 mL (-8.10,-250 
1.44) and -2.77 mL (-4.66,-0.89), respectively, but not on placebo juice (n=47): -1.56 mL (-251 
1.67,4.80) and -0.40 mL (-1.43,2.22). The reduction in LVMI from baseline was similar 252 
between nitrate-containing and placebo juices, with no difference between interventions.  253 
Therefore, the ratio between LV mass and volume – the M/V ratio, increased by 0.04 254 
(0.00,0.07) between active and nitrate-containing beetroot juices. Relative to baseline, LAVI 255 
fell on active juice: -1.59 ml/m2 (-2.64,-0.54), but not placebo juice: -0.26 ml/m2 (-1.29,0.78); 256 
however, there was no difference between the interventions: -1.33(-2.83,0.17).  257 
 258 
In contrast to nitrate, the only between-group difference in morphological parameters with 259 
spironolactone (n=44) was a marginal reduction in relative wall thickness (RWT): -0.01(-260 
0.02,0.00) vs doxazosin (n=43); see Table 2. Whilst spironolactone reduced LVMI relative to 261 
baseline: -1.48 g/m2.7 (-2.08, -0.88), there was no difference versus doxazosin: -0.85 g/m2.7 (-262 
1.76,0.05). Similarly, LAVI appeared to be reduced by doxazosin relative to baseline: -1.16 263 
ml/m2 (-2.24,-0.07), but not versus spironolactone. 264 
 265 
Echocardiographic Systo-Diastolic Function 266 
Among parameters of systo-diastolic function, the E/A ratio fell on spironolactone from 267 
baseline: -0.07 (-0.12,-0.02), and versus doxazosin: -0.12 (-0.19,-0.04)); see Figure 6 (A-B).  268 
The tissue Doppler systolic function index, S’, increased on spironolactone versus doxazosin, 269 
by 0.52 cm/s (0.05, 1.00); see Figure 6 (C-D).  270 
The only change in systo-diastolic function parameters observed with nitrate-containing 271 
beetroot juice was a prolongation of the deceleration time (DT) by 19.50 ms (8.40, 30.60) and 272 
19.74 ms (4.47,36.01) relative to baseline and nitrate-depleted juice, respectively. 273 
 274 
275 
Discussion  276 
We found that 6 months’ intervention with dietary nitrate as beetroot juice may reduce LV 277 
volumes (EDV and ESV) compared to placebo nitrate-depleted juice. The lack of any change 278 
in LV mass by active juice suggests a favourable effect of nitrate on LV structure and 279 
possibly myocardial wall stress (since LV volumes were reduced, whilst BP was unaffected). 280 
In addition, spironolactone decreased RWT, suggesting a beneficial effect on myocardial 281 
remodelling, and improved parameters of systo-diastolic function (S’, E/A) compared to 282 
doxazosin. These effects were also independent of BP (which was not different between 283 
spironolactone and doxazosin).  284 
 Nitrate’s chronic effect on reducing LV volumes have important implications for HFpEF, 285 
and builds on the beneficial acute actions of nitrate/nitrite recently demonstrated on exercise 286 
performance and left heart filling pressures (PCWP), in patients with HFpEF [36-39]. Indeed, 287 
across two randomised double-blind placebo-controlled studies by Borlaug and colleagues, 288 
one in 28 patients [37], the other in a subset of 52 of 98 patients with HFpEF [39], who were 289 
undergoing invasive haemodynamic exercise testing, sodium nitrite (either intravenous or 290 
nebulised-inhaled) acutely decreased aortic wave reflections (at rest), improved arterial 291 
compliance, elastance and central hemodynamics (during exercise), and left heart filling 292 
pressures (pulmonary capillary wedge pressure [PCWP]), compared to placebo [37]. 293 
However, no clinical data are available on the long-term effects of dietary nitrate on cardiac 294 
structure and function. This is a key question, given the problems of tolerance associated with 295 
organic nitrates. Therefore, the current study provides the most extensive evidence to date of 296 
long-term cardiac effects of dietary nitrate and has biological plausibility, building on the 297 
translational study of 9 weeks’ supplementation with oral nitrite showing decreased EDV and 298 
ESV versus placebo in the mouse model of pressure-overload induced LVH with trans-aortic 299 
constriction [7]. Regarding the specific changes in ventricular volumes in our study, it can be 300 
speculated that dietary nitrate-derived nitrite likely acts on ventricular pre-load by influencing 301 
venous dilatation [22, 40], and pressure; though since nitrate salts are also known to have 302 
diuretic activity, this could play a role. No direct measures of pre-load were collected here; 303 
however, changes in indirect parameters, such as ventricular volumes, as demonstrated with 304 
intravenous organic nitrate therapy [41]) support this. Indeed, previous invasive studies have 305 
used EDV to define LV pre-load [42, 43]. Moreover, the reduction in LV volumes, but not 306 
LVMI, resulted in an increased M/V ratio. This suggests a positive action on cardiac 307 
remodelling [44] and myocardial wall stress [45], with potential favourable prognostic 308 
implications [46]. 309 
In contrast to nitrate, ventricular volumes were not altered by spironolactone, which instead 310 
improved other structural and functional cardiac parameters. Spironolactone has previously 311 
been demonstrated to improve cardiac hypertrophy and remodelling in hypertensive patients 312 
[47], although this was not shown in patients with T2DM [48].  In our population, there was 313 
some evidence that spironolactone decreased RWT and LVMI, suggesting a direct action of 314 
spironolactone on cardiac remodelling (that was independent of BP). If confirmed, this 315 
finding would be relevant because cardiac remodelling is a prognostic factor for CV events - 316 
even in the absence of LVH [49].  317 
Our results also suggest important differential actions of the two drugs on cardiac 318 
performance (S’ and E/A).  S’ is considered a sensitive TDI index of systolic function [50] 319 
which was increased by spironolactone compared with doxazosin. 320 
Spironolactone has previously been found to have beneficial effects on diastolic function [51, 321 
52]. In subclinical diabetic cardiomyopathy, spironolactone decreased conventional Doppler 322 
parameters (E/A), without affecting E/E’ [47], despite evidence of elevated LV diastolic 323 
filling pressure (E/E’ 14.3±7). We also observed a reduction in E/A ratio with spironolactone, 324 
with no change in E/E’, which was within the normal range at baseline. Therefore, the 325 
reduction in E/A may reflect an improvement in diastolic function that is not limited to 326 
alterations in pre-load, since other parameters sensitive to pre-load, such as EDV, ESV and 327 
LAVI were not affected by spironolactone, Table 2, (and neither were blood pressure or heart 328 
rate).  However, diastolic function is a complex phenomenon and a “single parameter” 329 
approach does not provide a comprehensive overview [34].  330 
Overall, these results indicate that dietary nitrate may have BP-independent beneficial actions 331 
on myocardial remodelling over and above established effects of spironolactone. This could 332 
be explained by different mechanisms of action – mainly cardiac pre-load for dietary nitrate 333 
versus a direct anti-remodelling effect for spironolactone; although a direct action of 334 
nitrate/nitrite on the myocardium cannot be excluded and should be further investigated.  335 
We acknowledge several limitations of our study: cardiac analysis was not the primary 336 
outcome of the Vasera trial and our analyses are therefore exploratory; the overall sample 337 
size was relatively small (87 patients with follow-up data); confidence intervals are therefore 338 
wide; follow up data was incomplete, and the mixed effects model may not adequately 339 
account for any bias this could have introduced. 340 
 341 
342 
Conclusion 343 
Six months' dietary nitrate decreased LV volumes ~5%, representing sustained, BP-344 
independent effects on cardiac structure, suggesting a beneficial action on cardiac 345 
remodelling, with potential consequences on CV prevention/treatment. Spironolactone 346 
independently decreased LV wall thickness and modified parameters of systo-diastolic 347 
function. 348 
 349 
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Table 1: Baseline Clinical and Cardiac Parameters of the Study Population  
  Doxazosin Spironolactone 
Placebo Juice Active Juice Placebo Juice Active Juice 
Patients n 27 16 20 24 
Sex -female n (%) 6 (22) 5 (31) 8 (40) 8 (33) 
Diabetes -at risk n (%) 11 (41) 6 (38) 6 (30) 12 (50) 
Previous CV event n (%) 1 ( 3.7) 2 (12.5) 2 (10.0) 2 (8.3) 
Smoker n (%) 3 (12.0) 2 (15.4) 2 (13.3) 1 (5.6) 
Age (years) mean (SD) 54.9 (13.8) 58.4 (14.7) 58.2 (9.9) 57.1 (13.2) 
BMI- Kg/m2) Mean (SD) 30.2 (5.1) 32.7 (6.5) 33.0 (4.2) 33.7 (5.2) 
SBP (mmHg) Mean (SD) 135.1 (16.8) 134.3 (16.6) 139.2(17.6) 138.3 (21.6) 
DBP (mmHg)  Mean (SD) 79.4 (11.1) 80.7 (8.2) 79.8 (11.8) 83.1 (15.6) 
HR (beat/min) Mean (SD) 73.3 (14.4) 70.2 (11) 73 (13.1) 66.7 (10.4) 
LAVI (ml/m2) Mean(SD) 23.0 (8.4) 25.3 (8.6) 25.6 (9.8) 24.9 (6.9) 
LVMI (g/m2.7) Mean(SD) 52.7 (12.6) 50.9 (11.9) 54.1 (15.2) 51.8 (10.5) 
RWT Mean(SD) 0.401 (0.064) 0.389 (0.068) 0.403 (0.057) 0.373 (0.052) 
EDV (ml) Mean(SD) 127.4 (35.7) 138.4 (45.6) 127.6 (19.3) 134.7 (34.1) 
ESV (ml) Mean(SD) 53.6 (16.9) 63.9 (29.7) 55.3 (10.7) 57.5 (15.2) 
Mass/Volume (g/ml) Mean(SD) 0.96 (0.33) 0.81 (0.23) 0.88 (0.24) 0.81 (0.23) 
E/A Mean(SD) 1.00 (0.30) 0.98 (0.31) 1.09 (0.66) 0.94 (0.26) 
DT (msec) Mean(SD) 233.0 (51.6) 232.4 (59.9) 212.3 (59.0) 220.3(53.6) 
E/E’ Mean(SD) 7.55 (2.16) 8.38 (2.70) 7.63 (2.29) 7.50 (2.23) 
EF (%) Mean(SD) 58.20 (3.1) 54.90 (5.3) 56.80 (4.2) 57.4 (3.7) 
S’ (cm/s) Mean(SD) 9.0 (1.6) 9.0 (1.7) 8.8 (2.1) 8.8 (1.2) 
 
Table 1: Baseline clinical and cardiac parameters of the study population. Abbreviations: 
systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), left atrium 
volume index to body surface area (LAVI), left ventricular mass index (LVMI), relative wall 
thickness (RWT), end-diastolic volume (EDV), end-systolic volume (ESV), ratio of 
transmitral Doppler peak early (E) to late (A) filling velocity (E/A), ratio of transmitral 
Doppler peak early filling velocity (E) to pulsed-wave tissue-Doppler imaging (TDI)-derived 
early mitral annular diastolic velocity (E′) – (E/E’), early transmitral deceleration time (DT), 
ejection fraction (EF), pulsed-wave TDI-derived mitral annular systolic velocity – a systolic 
function index (S'), global longitudinal strain (GLS). 
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Table 2: Haemodynamic and Echocardiographic Parameters 
 
 Active 
juice 
(n=40) 
Placebo 
juice 
(n=47) 
Active vs 
placebo 
juice 
Spironolactone 
(n=44) 
Doxazosin 
(n=43) 
Spironolactone 
vs 
Doxazosin 
Haemodynamic  parameters 
SBP (mmHg) -6.34 (-
9.09,-
3.59) 
-6.57 (-
9.41,-3.73) 
0.23 (-3.77, 
4.22) 
-6.49 (-9.31,-
3.67) 
-6.42 (-
9.20,-
3.64) 
-0.07 (-4.07, 
3.93) 
DBP (mmHg) -5.06 (-
6.80,-
3.33) 
-4.96 (-
6.76,-3.17) 
-0.10 (-
2.63, 2.43) 
-5.19 (-6.96,-
3.42) 
-4.84 (-
6.59,-
3.09) 
-0.35 (-2.86, 
2.16) 
HR (bpm) 0.14 (-
1.51, 1.79) 
-0.94 (-
2.65, 0.76) 
1.08 (-1.33, 
3.49) 
-0.05 (-1.73, 
1.63) 
-0.76 (-
2.41, 0.89) 
0.71 (-1.67, 
3.09) 
Morphological parameters 
LAVI (ml/m2) -1.59 (-
2.64, -
0.54) 
-0.26 (-
1.29, 0.78) 
-1.33 (-
2.83, 0.17) 
-0.69 (-1.69, 
0.32) 
-1.16 (-
2.24, -
0.07) 
0.47 (-1.05, 
1.99) 
LVMI (g/m2.7) -0.96 (-
1.60, -
0.32) 
-1.16 (-
1.75, -0.57) 
0.20 (-0.68, 
1.09) 
-1.48 (-2.08, -
0.88) 
-0.63 (-
1.28, 0.01) 
-0.85 (-1.76, 
0.05) 
RWT -0.00 (-
0.01, 0.00) 
-0.00 (-
0.01, 0.00) 
-0.00 (-
0.01, 0.01) 
-0.001 (-0.01, -
0.00) 
0.00 (-
0.00, 
0.001) 
-0.01 (-0.02, -
0.00) 
EDV (ml) -4.77 (-
8.10, -
1.44) 
1.56 (-1.67, 
4.80) 
-6.33 (-
11.1, -1.57) 
-2.36 (-5.52, 
0.79) 
-0.85 (-
4.26, 2.59) 
-1.51 (-6.28, 
3.25) 
ESV (ml) -2.77 (-
4.66, -
0.89) 
0.40 (-1.43, 
2.22) 
-3.17 (-
5.86, -0.48) 
-1.52 (-3.31, 
0.27) 
-0.86 (-
2.78, 1.07) 
-0.67 (-3.37, 
2.03) 
Mass/Volume 
(g/ml) 
0.01 (-
0.01, 0.03) 
-0.03 (-
0.05, -0.00) 
0.04 (0.00, 
0.07) 
-0.01 (-0.03, 
0.02) 
-0.01 (-
0.03, 0.02) 
0.00 (-0.03, 
0.04) 
Systo-diastolic function  parameters 
E/A -0.00 (-
0.05, 0.10) 
-0.03 (-
0.07, 0.02) 
0.02 (-0.05, 
0.10) 
-0.07(-0. 12, -
0.02) 
0.05 (-
0.01, 0.10) 
-0.12 (-0.19, -
0.04) 
DT (ms) 19.50 
(8.40, 
30.60) 
-0.24 (-
10.6, 
10.08) 
19.74 
(4.47, 
36.01) 
11.32 (0.82, 
21.82) 
7.93 (-
3.42, 
19.26) 
3.39 (-12.5, 
19.25) 
E/E’ 0.26 (-
0.15, 0.68) 
-0.19 (-
0.57, 0.19) 
0.45 (-0.12, 
1.02) 
-0.13 (-0.53, 
0.26) 
0.21 (-
0.21, 0.62) 
-0.34 (-0.93, 
0.24) 
EF (%) 0.46 (-
0.29, 1.21) 
0.09 (-0.64, 
0.81) 
0.38 (-0.69, 
1.45) 
0.38 (-0.34, 
1.10) 
0.17 (-
0.60, 0.94) 
0.21 (-0.88, 
1.29) 
S’ (cm/s) -0.19 (-
0.53, 0.15) 
0.02 (-0.29, 
0.34) 
-0.21 (-
0.68, 0.26) 
0.18 (-0.14, 
0.50) 
-0.35 (-
0.68, -
0.52 (0.05, 
1.00) 
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0.01) 
GLS (%) 0.72 (-
0.43, 1.87) 
-0.58 (-
1.88, 0.72) 
1.30 (-0.48, 
3.08) 
-0.44 (-1.68, 
0.80) 
0.58 (-
0.61, 1.78) 
-1.02 (-2.77, 
0.73) 
 
 
Table 2: Change from baseline, active nitrate-containing beetroot juice versus the placebo 
nitrate-depleted juice, and spironolactone versus doxazosin. Least square means (LSM) 
estimated from a model using data from all follow up visits, adjusted for baseline value, 
gender age, ethnicity and diagnosis of diabetes. Data shown as LSM and 95% confidence 
intervals (CIs). Sets of data where the 95% CIs do not cross zero are highlighted in bold. 
Abbreviations: systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate 
(HR), left atrium volume index to body surface area (LAVI), left ventricular mass index 
(LVMI), relative wall thickness (RWT), end-diastolic volume (EDV), end-systolic volume 
(ESV), ratio of transmitral Doppler peak early (E) to late (A) filling velocity (E/A), ratio of 
transmitral Doppler peak early filling velocity (E) to pulsed-wave tissue-Doppler imaging 
(TDI)-derived early mitral annular diastolic velocity (E′) – (E/E’), early transmitral 
deceleration time (DT), ejection fraction (EF), pulsed-wave TDI-derived mitral annular 
systolic velocity – a systolic function index (S'), global longitudinal strain (GLS). 
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Figure Legends 
Figure 1. Study Flow Diagram. At Visit 2, spironolactone dosage regimen was 12.5mg once 
daily for one week titrated to twice daily (indicated in the Diagram as (1-2x/d)); doxazosin 
was 2mg once daily for one week titrated to twice daily (indicated in the Diagram as (1-
2x/d)). At Visit 5 the doses of each were doubled, but frequencies maintained at twice daily 
(2x/d). 
Figure 2. CONSORT flow diagram for VaSera trial and subsample of participants who had 
an echo at baseline and follow up visits. 
Figure 3. Blood pressure (BP) responses to spironolactone and doxazosin: (A) change from 
baseline in systolic BP (SBP) for spironolactone and doxazosin; (B) overall effect of 
spironolactone versus doxazosin on SBP; (C) change from baseline in diastolic BP (DBP) 
for spironolactone and doxazosin; (B) overall effect of spironolactone versus doxazosin on 
DBP. Data shown as least square means (LSM) with 95% Confidence Intervals. 
Figure 4. Blood pressure (BP) responses to dietary nitrate (beetroot juice): (A) change from 
baseline in systolic BP (SBP) for active nitrate-containing beetroot juice and placebo nitrate-
depleted juice; (B) overall effect of active nitrate-containing beetroot juice versus placebo 
nitrate-depleted juice on SBP; (C) change from baseline in diastolic BP (DBP) for active 
nitrate-containing beetroot juice and placebo nitrate-depleted juice; (B) overall effect of 
active nitrate-containing beetroot juice versus placebo nitrate-depleted juice on DBP. Data 
shown as least square means (LSM) with 95% Confidence Intervals. 
Figure 5. Left ventricular (LV) volume responses, measured by echocardiography, to 
dietary nitrate (beetroot juice): (A) change from baseline in LV end-diastolic volume 
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(LVEDV) for active nitrate-containing beetroot juice and placebo nitrate-depleted juice; (B) 
overall effect of active nitrate-containing beetroot juice versus placebo nitrate-depleted juice 
on LVEDV; (C) change from baseline in LV end-systolic volume (LVESV) for active 
nitrate-containing beetroot juice and placebo nitrate-depleted juice; (B) overall effect of 
active nitrate-containing beetroot juice versus placebo nitrate-depleted juice on LVESV. 
Data shown as least square means (LSM) with 95% Confidence Intervals. 
Figure 6. Echocardiographic systo-diastolic responses to spironolactone and doxazosin: (A) 
change from baseline in E/A ratio for spironolactone and doxazosin; (B) overall effect of 
spironolactone versus doxazosin on E/A ratio; (C) change from baseline in tissue Doppler 
systolic function index (S’) for spironolactone and doxazosin; (B) overall effect of 
spironolactone versus doxazosin on S’. Data shown as least square means (LSM) with 95% 
Confidence Intervals. 
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 Figure 1: Study Flow Diagram.  555 
 556 
 557 
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Figure 2 CONSORT flow diagram for VaSera trial and subsample of participants 558 
who had an echo at baseline and follow up visits. 559 
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